OOIR: Observatory of International Research

Papers

(The H4-Index of npj Vaccines is 41. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Author Correction: Protective antibody response following oral vaccination with microencapsulated Bacillus Anthracis Sterne strain 34F2 spores	299
Assessing immunogenicity barriers of the HIV-1 envelope trimer	232
Reverse development of vaccines against antimicrobial-resistant pathogens	183
Analyzing atomic force microscopy images of virus-like particles by expectation-maximization	133
Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine	113
Functionality and translation fidelity characterization of mRNA vaccines using platform based mass spectrometry detection	110
Impact of genotypic variability of measles virus T-cell epitopes on vaccine-induced T-cell immunity	109
Zika purified inactivated virus (ZPIV) vaccine reduced vertical transmission in pregnant immunocompetent mice	100
Influenza A virus in dairy cattle: infection biology and potential mammary gland-targeted vaccines	93
Effective vaccination strategy using SARS-CoV-2 spike cocktail against Omicron and other variants of concern	89
Risk assessment of retinal vascular occlusion after COVID-19 vaccination	79
INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants	77
Rational development of a combined mRNA vaccine against COVID-19 and influenza	76
Immunogenic arenavirus vector SIV vaccine reduces setpoint viral load in SIV-challenged rhesus monkeys	74
Intranasal vaccine for Lyme disease provides protection against tick transmitted Borrelia burgdorferi beyond one year	71
Mapping global public perspectives on mRNA vaccines and therapeutics	60
The dengue-specific immune response and antibody identification with machine learning	60
A potent and durable malaria transmission-blocking vaccine designed from a single-component 60-copy Pfs230D1 nanoparticle	59
Baseline mapping of Oropouche virology, epidemiology, therapeutics, and vaccine research and development	58
Protein engineering strategies for rational immunogen design	58
LmCen−/− based vaccine is protective against canine visceral leishmaniasis following three natural exposures in Tunisia	57
Immune response against SARS-CoV-2 variants: the role of neutralization assays	57
PfRH5 vaccine; from the bench to the vial	57
Microneedle patch as a new platform to effectively deliver inactivated polio vaccine and inactivated rotavirus vaccine	57
Author Correction: A Pvs25 mRNA vaccine induces complete and durable transmission-blocking immunity to Plasmodium vivax	56

A rationally designed antigen elicits protective antibodies against multiple nosocomial Gram-positive pathogens	56
Next-gen novel nanocage-based multivalent vaccine candidate to tackle the rising menace of Mpox	54
Genome-wide association study of myocarditis and pericarditis following COVID-19 vaccination	54
A field test of empathetic refutational and motivational interviewing to address vaccine hesitancy among patients	50
Single-dose intranasal adenovirus-based RSV vaccines targeting G and M2	49
Restricted valency (NPNA)n repeats and junctional epitope-based circumsporozoite protein vaccines against Plasmodium falciparum	49
Leishmania tarentolae as a platform for the production of vaccines against viral pathogens	48
A register and questionnaire study of long-term general health symptoms following SARS-CoV-2 vaccination in Denmark	47
Multicomponent intranasal adjuvant for mucosal and durable systemic SARS-CoV-2 immunity in young and aged mice	46
IL-12 mRNA-LNP promotes dermal resident memory CD4+ T cell development	45
Immunogenicity and protective efficacy of a rhesus adenoviral vaccine targeting conserved COVID-19 replication transcription complex	45
Use of equine H3N8 hemagglutinin as a broadly protective influenza vaccine immunogen	45
Antibody responses against influenza A decline with successive years of annual influenza vaccination	44
Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants	43
GP38 as a vaccine target for Crimean-Congo hemorrhagic fever virus	43
Multivalent cytomegalovirus glycoprotein B nucleoside modified mRNA vaccines did not demonstrate a greater antibody breadth	41